A Study Of PF-05280586 (Rituximab-Pfizer) Or MabTheraÂ® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)